Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

5.130 -0.280 (-5.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Jaguar Health, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Jaguar Health Reports First Quarter 2023 Financial Results
Via ACCESSWIRE
Canalevia-CA1, Jaguar Animal Health’s FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs, Now Available from Chewy
Via ACCESSWIRE
Jaguar Health Launches AI-powered Web Portal to Support Patient Access to Mytesi, the Company's FDA-approved Prescription Drug
Via ACCESSWIRE
Jaguar Completes Enrollment in Its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea
Via ACCESSWIRE
Jaguar Health to Hold Investor Webcast Monday, May 15th at 8:30 AM EDT Regarding Q1 2023 Financials & Corporate Updates
Via ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
Napo Therapeutics Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress in Abu Dhabi
Via ACCESSWIRE
U.S. Veterinary Oncologists Participating in a New Survey Prefer Canalevia-CA1 Over the Current Standard of Care
Via ACCESSWIRE
Patient Enrollment Surpasses 90% in Jaguar Health's Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea
Via ACCESSWIRE
Jaguar Health Reports 2022 Financial Results - Prescription Revenues up 179% to $11.9 Million
Via ACCESSWIRE
Jaguar Health Provides Update on Monitoring Trading Activity to Identify Possible Illegal Short Selling
Via ACCESSWIRE
Jaguar Animal Health Exhibiting at Veterinary Cancer Society Collaborative Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Via ACCESSWIRE
Jaguar Health Announces Time Change for March 27th Investor Webcast to 8:00 AM EDT
Via ACCESSWIRE
Leading Cancer Patient Advocate Kelly Shanahan, M.D., Joins Jaguar Health's Scientific Advisory Board
Via ACCESSWIRE
Jaguar Health to Hold Investor Webcast Monday, March 27th at 8:30 AM EDT Regarding Q4 2022 Financials & Corporate Updates
Via ACCESSWIRE
Jaguar Health Celebrates U.N. International Day of Forests with Milestone of Providing Income to 20,000+ People Living in Tropical Rainforest Communities
Via ACCESSWIRE
Jaguar Health Leveraging AI to Support Patient Access to Mytesi, the Company's FDA-Approved Prescription Drug
Via ACCESSWIRE
Jaguar Health to Present at BioTrinity 2023 Conference’s R&D Spotlight on Rare Diseases
Via ACCESSWIRE
Jaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug Crofelemer
Via ACCESSWIRE
FDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the US
Via ACCESSWIRE
Jaguar Health Achieves Approximately 75% Enrollment in Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea
Via ACCESSWIRE
Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.
Via ACCESSWIRE
Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement
Via ACCESSWIRE
Jaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar’s 2023 Focus on Human Drug Development
Via ACCESSWIRE
Jaguar Health Engages Shareholder Intelligence Services, LLC (ShareIntel) to Monitor Trading Activity in Effort to Identify Possible Illegal Short Selling
Via ACCESSWIRE
Jaguar Health Engages Former FDA Gastroenterology Division Deputy Director Andrew Mulberg, M.D. to Bolster Company's Regulatory Expertise
Via ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
Jaguar Health Provides Updates Regarding Company's Focus on Rare and Orphan Disease Indications in the U.S. & Europe
Via ACCESSWIRE
Jaguar Health Announces Completion of Key Milestone in Process of Establishing Indena S.p.A. as a Reliable Approved Crofelemer Manufacturer
Via ACCESSWIRE
Jaguar Health Announces Establishment of Board of Directors for Newly Formed Joint Venture Magdalena Biosciences
Via ACCESSWIRE
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.